What Is Theravance Biopharma, Inc. (TBPH) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Theravance Biopharma, Inc.'s intrinsic value is estimated at a composite fair value of $13.31. Trading at $16.93, the stock is approaching fair value or slight overvaluation (implied return of -21.4%), as 8 of 12 models suggest limited further upside. Model dispersion is worth noting: RCMH-DCF targets $20.58 (+21.5%), versus Sentiment SOTP at $6.82 (-59.7%). This +81.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About TBPH?
12 of 13 models are currently active for TBPH. Of these, 3 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates TBPH's intrinsic value at $11.93, implying -29.5% downside from the current price. See which stocks rank higher →
How Does TBPH Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, TBPH ranks #107 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Theravance Biopharma, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is TBPH a Value Trap?
CirclFi's Value Trap algorithm assigns TBPH a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Theravance Biopharma, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Theravance Biopharma, Inc. scores 6.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +81.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every TBPH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across TBPH's 12 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad